About: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
Creator	Montesarchio, Vincenzo Ascierto, Paolo Atripaldi, Luigi Bianco, Antonella Celentano, Egidio Curvietto, Marcello D'abbraccio, Maurizio De Rosa, Rosanna Fraganza, Fiorentino Grimaldi, Antonio Iommelli, Chiara Lewis Million-Weaver, Samuel Mallardo, Domenico Manzillo, Elio Murino, Patrizia Palla, Marco Palumbo, Cristiana Parella, Roberto Rea, Gaetano Trojaniello, Claudia Vitale, Maria
Source	Medline; PMC
abstract	BACKGROUND: The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and interleukin 6 (IL-6). Initial reports from the outbreak in Italy, China and the USA have provided anecdotal evidence of improved outcomes with the administration of anti-IL-6 agents, and large-scale trials evaluating these therapies are ongoing. STUDY DESCRIPTION: In this retrospective case series, clinical outcomes and correlates of response to treatment with the IL-6 receptor antagonist sarilumab are described for 15 patients with COVID-19 from a single institution in Southern Italy. Among 10 patients whose symptoms improved after sarilumab treatment, rapid decreases in CRP levels corresponded with clinical improvement. Lower levels of IL-6 at baseline as well as lower neutrophil to lymphocyte ratio as compared with patients whose COVID-19 did not improve with treatment were associated with sarilumab-responsive disease. CONCLUSIONS: This observation may reflect a possible clinical benefit regarding early intervention with IL-6-modulatory therapies for COVID-19 and that CRP could be a potential biomarker of response to treatment.
has issue date	2020-08-11(xsd:dateTime)
bibo:doi	10.1136/jitc-2020-001089
bibo:pmid	32784217
has license	cc-by-nc
sha1sum (hex)	24174fbadf29581910febace477a36be9c6ce3cb
schema:url	https://doi.org/10.1136/jitc-2020-001089
resource representing a document's title	Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
has PubMed Central identifier	PMC7418768
has PubMed identifier	32784217
schema:publication	J Immunother Cancer
resource representing a document's body	covid:24174fbadf29581910febace477a36be9c6ce3cb#body_text
is schema:about of	named entity 'receptor antagonist' named entity 'interleukin' named entity 'interleukin 6' named entity 'IL-6' named entity 'infection' named entity '95% CI' named entity 'mechanical ventilation' named entity 'adaptive immune response' named entity 'embolism' named entity 'symptom' named entity 'IL-6' named entity 'ground-glass opacities' named entity 'cohort study' named entity 'pathology' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'open-label trial' named entity 'mediastinal' named entity '5.2' named entity 'COVID' named entity 'IL-1β' named entity 'platelet counts' named entity 'Wuhan' named entity 'Pneumonia' named entity 'normal weight' named entity 'invasive mechanical ventilation' named entity 'IL-6' named entity 'sarilumab' named entity 'older age' named entity 'mononuclear cells' named entity 'ARDS' named entity 'neutrophil' named entity 'physical distancing' named entity 'infection' named entity 'biomarkers' named entity 'mortality rate' named entity 'CRS' named entity 'lungs' named entity 'NLR' named entity 'sarilumab' named entity 'IL-6' named entity 'SARS-CoV-2' named entity 'sarilumab' named entity 'phase II' named entity 'sarilumab' named entity 'fatality rate' named entity 'infection' named entity 'low point' named entity 'patients' medical records' named entity 'hematological' named entity 'IL-6' named entity 'sarilumab' named entity 'immune cells' named entity 'intubated' named entity 'China' named entity 'CT scans' named entity 'hepatitis B virus' named entity 'tocilizumab' named entity 'clinical research' named entity 'biomarkers' named entity 'Italy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software